{
    "clinical_study": {
        "@rank": "15032", 
        "arm_group": {
            "arm_group_label": "haemodialysis vascular access using ePTFE grafts"
        }, 
        "brief_summary": {
            "textblock": "Multicentre, prospective, observational post-market registry. To monitor and collect data on\n      the post-market clinical safety and performance of the Vascutek Rapidax II Vascular Access\n      Graft."
        }, 
        "brief_title": "The Vascutek Rapidax\u2122 II Post Market Surveillance Registry", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "End Stage Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "At least 10 patients who have been implanted with a Rapidax II Vascular Access Graft for\n      haemodialysis applications in patients with End Stage Renal Disease (ESRD), who are\n      undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic\n      graft.\n\n      Primary End Points:Safety and Performance\n\n        -  Secondary patency at 6 months post implant (Performance).(access survival until\n           abandonment). The interval from time of implant  to abandonment or time of measurement\n           of patency, including intervention to re-establish the functionality of the thrombosed\n           access\n\n        -  Secondary patency at 12 months post implant (Performance.(access survival until\n           abandonment). The interval from time of implant  to abandonment or time of measurement\n           of patency, including intervention to re-establish the functionality of the thrombosed\n           access\n\n        -  Freedom from device related Serious Adverse Events at 6 and 12 months (Safety)\n\n      Secondary End Points: Safety and performance\n\n        -  Primary patency at 6 months post implant (Performance. (intervention free access\n           survival). The interval from time of implant to any intervention designed to maintain\n           or re-establish patency or to access thrombosis\n\n        -  Primary patency at 12 months post implant (Performance).(intervention free access\n           survival). The interval from time of implant to any intervention designed to maintain\n           or re-establish patency or to access thrombosis\n\n        -  Assisted primary patency at 6 months (Performance. (thrombosis free access survival).\n           The interval from time of implant to intervention to maintain patency prior to the\n           occurrence of thrombosis\n\n        -  Freedom from device related Serious Adverse Events at 6 and 12 months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is \u2265 18 and \u2264 90 years old\n\n          2. Subject has a life expectancy of at least 12 months\n\n          3. Subject is scheduled to undergo placement of a new straight or loop arm\n             arteriovenous haemodialysis access graft\n\n          4. The subject is willing and able to comply with the protocol and associated follow up\n             requirements\n\n          5. Subjects must have agreed for their data to be entered into the registry as per the\n             local hospital consent procedure\n\n        Exclusion Criteria:\n\n          1. Known allergy or sensitivity to ePTFE\n\n          2. Subject unwilling or unable to comply with the protocol\n\n          3. Life expectancy of less than 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "At least 10 patients who have been implanted with a Rapidax II Vascular Access Graft for\n        haemodialysis applications in patients with End Stage Renal Disease (ESRD), who are\n        undergoing or are scheduled to begin haemodialysis and require implant of a prosthetic\n        graft."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01977508", 
            "org_study_id": "VAG-001"
        }, 
        "intervention": {
            "arm_group_label": "haemodialysis vascular access using ePTFE grafts", 
            "intervention_name": "ePTFE vascular access grafts", 
            "intervention_type": "Device", 
            "other_name": "RapidaxTM II Vascular access graft"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vascular access grafts", 
            "Haemodialysis"
        ], 
        "lastchanged_date": "October 30, 2013", 
        "location": {
            "contact": {
                "email": "d.cater@vascutek.com", 
                "last_name": "david Cater", 
                "phone": "0141 814 5676"
            }, 
            "facility": {
                "address": {
                    "city": "Glasgow", 
                    "country": "United Kingdom", 
                    "zip": "PA49RR"
                }, 
                "name": "Vascutek Ltd"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "d.cater@vascutek.com", 
            "last_name": "David Cater", 
            "phone": "0141 814 5676"
        }, 
        "overall_official": {
            "affiliation": "Klinik f\u00fcr Gef\u00e4\u00dfchirurgie/Gef\u00e4\u00dfzentrum", 
            "last_name": "Bernd Lobenstein", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Secondary patency at 6 months post implant (Performance)", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Secondary patency at 12 months post implant (Performance)", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from device related Serious Adverse Events at 6 and 12 months (Safety)", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01977508"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Primary patency at 6 months post implant (Performance)", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Primary patency at 12 months post implant (Performance)\n\u2022", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Assisted primary patency at 6 months (Performance)\n\u2022", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Freedom from device related Serious Adverse Events at 6 and 12 months", 
                "measure": "Safety and Performance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Vascutek Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vascutek Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "1 Year", 
        "verification_date": "October 2013"
    }
}